Introduction: Surgical therapy for benign prostatic hyperplasia (BPH) is generally reserved for patients with severe symptoms. Single-port (SP) robot-assisted simple prostatectomy (RASP) is a novel evolving approach. Our aim is to report its advantageous outcomes. Methods: Single-center, three-surgeon case series of 99 consecutive SP RASP from February 2019 to October 2022. The procedure consists of two main steps. Step one is to excise the obstructive adenoma up to the verumontanum. Step two consists of a 360° mucosal flap reconstruction of the bladder neck. Data were recollected prospectively and analysis was done with descriptive statistics. Results: All cases were completed successfully, without the need for extra ports or conversion. A total of 97 cases were done transvesically and 2 were done through a transperitoneal approach. 45.4% and 17.1% had history of previous abdominal and prostate interventions, respectively. The most common indication was urinary retention (59.5%). Median estimated blood loss was 100 ml and median operative time was 185 min. Most of the patients (76.7%) were discharged within 24 hours, with a median pain score of 2.5. Median length of stay was 5.6 hours in planned outpatient cases. Upon discharge, 77.8% of patients did not need narcotics. The median duration of Foley catheter was 5 days. The preoperative median IPSS, maximum flow rate, and PVR were 21, 6 ml/sec, and 156.5 ml, respectively. All of which improved through time (Figure 1). Readmission rate was 0%. Conclusions: SP RASP is a feasible procedure that includes reconstruction of the mucosal flap after excision of the adenoma. SOURCE OF Funding: None.
